Former Microsoft Research Lab- Asia Deputy Director Dr. Jonathan Tian（田江森） Visits ReBlood Group to Discuss AI-Driven Health Management
On Friday afternoon, March 21, 2025, Dr. Jonathan Tian（田江森）, former Deputy Director of Microsoft Research Lab- Asia and current Chief AI Scientist at Yushan.AI, visited ReBlood Group’s Health Regeneration Center at Tainan’s Argosy Yacht City. During this high-profile meeting with ReBlood Group, both parties aimed to explore and implement innovations in AI-driven health management through in-depth discussions.
Recently, the multinational ReBlood Group has announced an investment of tens of millions of NT Dollars to integrate Yushan AI, marking a significant advancement in the integration of technological innovation and health management. The company plans to leverage Yushan AI’s advanced on-premise technology to establish an automated production laboratory and a cutting-edge AI-driven consultation service.
Promoting Cross-Disciplinary Collaboration and Exploring Innovations in Health Management
This meeting aims to foster cross-disciplinary collaboration, with both parties focusing on cutting-edge technologies such as Large Language Models (LLM) and edge computing to identify key opportunities to drive innovation in health management. Drawing from nearly two decades of technical expertise and industry insights at Microsoft Research Lab- Asia, Dr. Tian will share his latest research findings and explore how AI can be integrated with ReBlood Group’s extensive experience in cellular anti-aging and holistic health industries to pioneer a new era of AI-driven advancements.
Guided by its development philosophy of “Longevity Trends, A Beautiful Life”, ReBlood Group remains dedicated to enhancing societal well-being through advanced biotechnology. With its expertise in advanced cellular technology and deep insights into the future of longevity, the company continues to innovate products and services that elevate the development of the global health industry.
ReBlood’s Future Outlook and Strategic Preparations
ReBlood Group CEO Sean Chen further stated:
"We have initiated our Pre-IPO preparations and expect to complete our cross-border restructuring by the second quarter of 2025. This collaboration with Yushan AI will accelerate our positioning in the Asia-Pacific intelligent biotechnology market."
Dr. Tian previously held positions at AT&T Bell Labs, SpaceLabs Medical, and Seattle-based startup bSQUARE. Since 2004, he accumulated extensive experience at Microsoft Research Lab- Asia and, after resigning as Deputy Director in 2023, joined Yushan.AI. Under his leadership, Yushan.AI has maintained its competitive edge in the global AI landscape, with a strong commitment to advancing the widespread application of Large Language Models (LLMs) and edge computing technologies.
The Key Role of AI in Personal Health Management
Dr. Tian stated:
"AI is at a pivotal turning point in personal health management, shifting from mere 'data analysis' to 'proactive intervention.' By integrating ReBlood’s foundational cellular technology with our algorithmic framework, we are poised to commercialize personalized anti-aging solutions. The rapid advancements in AI are transforming industries at an unprecedented pace, with businesses actively adopting AI-driven solutions. However, platforms alone only provide better resources—commercial success lies in identifying and addressing customer needs. This is a crucial moment for AI-driven transformation."
During this meeting, both parties held in-depth discussions on leveraging AI to predict diseases early, enhance the accuracy and efficiency of preventive medicine, and drive new competitive advantages in the healthcare sector. Looking ahead, ReBlood is committed to advancing AI-driven health management technologies within the cellular field. By fostering industry collaborations, the company aims to develop smart, personalized health management solutions tailored to diverse customer needs.
Additionally, ReBlood will continue driving innovation in biotechnology, enhancing safety and efficiency in longevity risk prevention and chronic disease management. These efforts will bring groundbreaking advancements to the health sector, ultimately improving the quality of life for customers.
Upcoming High-Level Forum and Future Collaboration Prospects
ReBlood is actively participating in the high-level forum “How AI is Transforming the Health and Financial Industries,” which will be held on March 27, 2025, at the NTU Hospital International Convention Center. The event will bring together leaders from industry, government, and academia to explore the latest trends in AI applications across multiple domains, including health management, smart finance, and edge computing.
This meeting not only marks a new milestone in cross-sector collaboration within the industry but also provides solid technological support for the commercialization of AI-driven solutions. Looking ahead, ReBlood aims to further expand the scope of its partnerships, jointly exploring and realizing the vast potential of AI applications in the health industry.
About ReBlood
ReBlood Group is a service-oriented company dedicated to addressing the challenges and opportunities arising from global aging and declining birth rates. The company provides innovative solutions to tackle the evolving needs in health, longevity, finance, and related derivative issues.
By integrating cutting-edge technologies and services in preventive medicine, precision medicine, and regenerative medicine, ReBlood Group is committed to offering comprehensive health management solutions. Its mission is to assist clients and their families in achieving the vision of “Health, Happiness, and Longevity”—or as expressed in Taiwanese: “呷百二” (Taiwanese phrase meaning living to 120 year-old in good health and joy).
Featured on:
📌 CNYes
📌 AASTOCKS
📌 Fengyun Academy
📌 Yahoo Finance
Copyright © 2025 ReBlood Inc.
版權所有